Olaparib

141 interactions 358 cited references
Also sold as: Lynparza Lynparza®
About Olaparib

Olaparib is used alone or in combination with bevacizumab (Avastin) to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) canc… Read the full Olaparib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dengue Tetravalent Vaccine, Live Bacillus Of Calmette And Guerin Vaccine, Live Measles Virus Vaccine, Live Mifepristone Levoketoconazole Yellow Fever Vaccine
12 Contraindicated 122 Major 7 Moderate
All (141) Contraindicated (12) Major (122) Moderate (7)

Contraindicated

Olaparib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Olaparib Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Olaparib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Mifepristone Korlym Increased olaparib exposure and an increased miFEPRIStone exposure Details Olaparib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Olaparib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Olaparib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Olaparib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Olaparib Cyclosporine Injection Atopica Increased olaparib exposure Details Olaparib Cyclosporine Ophthalmic Cequa Increased olaparib exposure Details Olaparib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Olaparib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Olaparib Ketoconazole Topical Extina® Foam Increased olaparib exposure Details Olaparib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Olaparib Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Olaparib Letermovir Injection Prevymis Increased olaparib exposure Details Olaparib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Olaparib Methylergonovine Methergine Increased methylergonovine exposure Details Olaparib Miconazole Buccal Oravig Increased olaparib exposure Details Olaparib Miconazole Topical Aloe Vesta Antifungal Increased olaparib exposure Details Olaparib Miconazole Vaginal Lagicam Increased olaparib exposure Details Olaparib Miconazole Aloe Vesta Antifungal Increased olaparib exposure Details Olaparib Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Olaparib Nafcillin Injection Unipen® Injection Decreased olaparib exposure and efficacy Details Olaparib Nifedipine Adalat® Increased NIFEdipine exposure Details Olaparib Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Olaparib Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Olaparib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Olaparib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Olaparib Alfentanil Increased ALfentanil exposure and an increased risk of respiratory depression Details Olaparib Amprenavir Increased olaparib exposure Details Olaparib Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Olaparib Aprepitant Aponvie Increased olaparib exposure Details Olaparib Artemether Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Olaparib Atazanavir Reyataz Increased olaparib exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.